2.94BMarket Cap
LossP/E TTM
Key Figures
71.500Open
71.570High
560.43KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.36%Turnover Ratio
71.140Prev. Close
67.160Low
27.13MTurnover
LossP/E Static
1.13P/B
0.00%Div Yield TTM
-13.99%ROA
118.84052wk High
0.98Volume Ratio
-2.03BNet Profit
41.13MShares
-10.3076EPS TTM
--Beta
-16.09%ROE
29.95052wk Low
6.20%Amplitude
-35.08%Gross Margin
2.94BMarket Cap
0.68Reward/Risk
4.69%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Grail Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 62 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 68.39.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Support & Resistance

Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Grail Inc Highlights
StrengthsRisks
Grail Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Ionis Pharmaceuticals Inc
IONS
26
Indicators
Financial Indicators
EPS

Relevant data have not been disclosed by the company yet.
Total revenue

Relevant data have not been disclosed by the company yet.
Grail Inc Info
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Ticker SymbolGRAL
CompanyGrail Inc
CEORagusa (Robert)
Websitehttps://grail.com/
Shareholders
FAQs
What is the current price of Grail Inc (GRAL)?
The current price of Grail Inc (GRAL) is 68.56.
What is the symbol of Grail Inc?
The ticker symbol of Grail Inc is GRAL.
What is the 52-week high of Grail Inc?
The 52-week high of Grail Inc is 118.84.
What is the 52-week low of Grail Inc?
The 52-week low of Grail Inc is 29.95.
What is the market capitalization of Grail Inc?
The market capitalization of Grail Inc is 2.82B.
Is Grail Inc (GRAL) currently rated as Buy, Hold, or Sell?
According to analysts, Grail Inc (GRAL) has an overall rating of Buy, with a price target of 68.39.
What is the Earnings Per Share (EPS TTM) of Grail Inc (GRAL)?
The Earnings Per Share (EPS TTM) of Grail Inc (GRAL) is -11.11.